Feed / SRRK

Scholar Rock Holding Corporation

SRRK

Healthcare · 58.42 +0.3% today

Isolated · not yet confirmedMarket checked 26 Aug, 09:45 GMT-4

Jodie situation report

Scholar Rock Holding Corporation's current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.

What changed
  • The operating loss narrowed by 3.2M.
  • Operating cash flow remained negative at -152.4M.
Company+0.3% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Completion of Phase 3 SAPPHIRE and Phase 1 DRAGON, with reported decreases in clinical/preclinical costs (including $1.1M decrease for SRK-181 and $2.5M for SRK-439).

Invalidation: The isolated read changes if SRRK's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind SRRK

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ABBVAbbVie Inc.partnerMar 3, 2026

For the latter, many companies, including AbbVie Inc, Roche, Bicara Therapeutics, Novartis, Bristol Myers Squibb (acquired Forbius) and Merck KGaA, Merck (acquired Tilos Therapeutics) are developing therapies for cancer immunotherapy in combination with CPI t…

BCAXBicara Therapeutics Inc.partnerMar 3, 2026

For the latter, many companies, including AbbVie Inc, Roche, Bicara Therapeutics, Novartis, Bristol Myers Squibb (acquired Forbius) and Merck KGaA, Merck (acquired Tilos Therapeutics) are developing therapies for cancer immunotherapy in combination with CPI t…

BMYBristol-Myers Squibb CompanypartnerMar 3, 2026

For the latter, many companies, including AbbVie Inc, Roche, Bicara Therapeutics, Novartis, Bristol Myers Squibb (acquired Forbius) and Merck KGaA, Merck (acquired Tilos Therapeutics) are developing therapies for cancer immunotherapy in combination with CPI t…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SRRK is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.